Interprofessional Care of Patients with Long-Chain Fatty Acid Oxidation Disorders

To participate in this activity, please:

Advances in treatment, notably nutritional supplementation with odd-carbon medium-chain triglycerides, have improved the quality of life of persons with long-chain fatty acid oxidation disorders (LC-FAODs). However,  the complexity and multisystem impact of these rare metabolic conditions requires a large, interprofessional, multidisciplinary care team to coordinate care over the lifespan. In addition to highlighting key concepts in patient management, this activity provides an overview of the principles of interprofessional collaboration and describes recommended roles for each member of the interprofessional care team.

Course Credit:

0.25 AAPA Category I CME Credit
0.25 ACPE Contact Hours
0.25 AMA PRA Category 1 CreditsTM
0.25 ANCC Contact Hours
0.25 CA-BRN Contact Hours

Dates:

Opens: 2025-11-14
Closes: 2026-11-14

Target Audience:

Dietitians, nurse practitioners, pharmacists, physician associates, and physicians who provide care to patients with long-chain fatty acid oxidation disorders.

This activity was self-funded by Annenberg Center for Health Sciences.

Accreditation

In support of improving patient care, the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 0.25 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

The Annenberg Center has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 hours AAPA Category 1 CME credits. Approval is valid until November 14, 2026. Physician Associates should only claim credit commensurate with the extent of their participation.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.25 ANCC contact hours.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 0.25 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

Additional Content Planners

Vamsi Ahobila, MD (Medical Writer)
No significant relationships to disclose.

Melissa Ketchum, CHCP (Planner)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Planner)
No significant relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Contributing Faculty

  • Christopher Flores, MD

    Family Medicine Physician
    Eisenhower Medical Center
    Rancho Mirage, California

  • LaTosha Mollette, DNP

    Family Nurse Practitioner
    Louisiana Family Medicine Clinic
    Jonesboro, Louisiana

  • Michael Smith, PharmD

    Clinical Pharmacist in Pain/Palliative Care
    University of Michigan
    Ann Arbor, Michigan

  • Sandra Carol van Calcar, PhD, RD, LD

    Associate Professor of Molecular and Medical Genetics
    School of Medicine
    Oregon Health and Science University
    Portland, Oregon

  • Jerry Vockley, MD, PhD

    University of Pittsburgh
    Cleveland Family Endowed Chair in Pediatric Research
    Professor of Human Genetics
    UPMC Children's Hospital of Pittsburgh
    Chief of Genetic and Genomic Medicine
    Director of the Center for Rare Disease Therapy
    Pittsburgh, Pennsylvania

Learning Objectives

  • Describe the evolution in the treatment landscape for patients with long-chain fatty acid oxidation disorders.
  • Identify strategies to improve interprofessional care of patients with long-chain fatty acid oxidation disorders.

Faculty Disclosures

Christopher Flores, MD

No relationships to disclose.

LaTosha Mollette, DNP

No relationships to disclose.

Michael Smith, PharmD

No relationships to disclose.

Sandra Carol van Calcar, PhD, RD, LD

No relationships to disclose.

Jerry Vockley, MD, PhD

Consultant: Acer, Agios Pharmaceuticals, Applied Therapeutics, Aro Biotherapeutics, BioMarin Pharmaceutical Inc., Frictionless Solutions, Horizon Therapeutics, Illumina Inc., Jaguar Gene Therapy, LogicBio Therapeutics, Orphan Labs, PTC Therapeutics, Sangamo Therapeutics, Inc., Sanofi, Satellite Bio, Society for Inherited Metabolic Disorders, WebMD Health Corp

Stock:  American Gene Technologies International, Inc.